Madrigal Reports Strong Rezdiffra Sales, Anticipates European Launch

Madrigal Pharmaceuticals reported strong financial results for the fourth quarter and full year of 2024, with net sales of $103 million in Q4 and $180 million for the year, largely driven by the successful launch of its MASH treatment, Rezdiffra. By the end of 2024, over 11,800 patients were using Rezdiffra, marking a significant milestone in its adoption among gastroenterologists and hepatologists. The company also announced promising two-year data from the Phase 3 MAESTRO-NAFLD-1 trial, showing significant reductions in liver stiffness among patients with compensated MASH cirrhosis. Despite a net loss of $465.9 million, Madrigal maintains a robust cash position and is optimistic about expanding Rezdiffra's indications and launching it in Europe by mid-2025. CEO Bill Sibold highlighted the monumental achievement of securing FDA approval for Rezdiffra, calling it a pivotal moment for the company and the MASH community. Looking ahead, Madrigal aims to further establish its leadership in the MASH treatment space, supported by ongoing clinical trials and potential regulatory approvals.